Trials / Completed
CompletedNCT03883633
Reversal of Cognitive Decline (ReCODE) Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- QuesGen Systems Inc · Academic / Other
- Sex
- All
- Age
- 45 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
Prospective study on patients enrolled in the ReCODE treatment protocol
Detailed description
The objective of the study is to determine if the ReCODE treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with Alzheimer's Disease (AD) and patients who are exhibiting Mild Cognitive Impairment (MCI). MCI is often a precursor to an AD diagnosis. For this study, there will be no distinction made between participants who have been diagnosed with AD and those who show signs of MCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | ReCODE Protocol | Functional medicine approach to address symptoms of Alzheimer's and cognitive decline |
Timeline
- Start date
- 2019-06-30
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2019-03-21
- Last updated
- 2021-01-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03883633. Inclusion in this directory is not an endorsement.